This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kimura, T.
Right arrow Articles by Yago, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kimura, T.
Right arrow Articles by Yago, K.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, April 2004, p. 1159-1167, Vol. 48, No. 4
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.4.1159-1167.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.

Population Pharmacokinetics of Arbekacin, Vancomycin, and Panipenem in Neonates

Toshimi Kimura,1* Keisuke Sunakawa,2 Nobuo Matsuura,3 Hiroaki Kubo,4 Shigehiko Shimada,1 and Kazuo Yago1

Department of Pharmacy,1 Division of Neonatology, Kitasato University Hospital,3 Division of Infectious Disease, Kitasato University School of Medicine, 1-15-1 Kitasato, Sagamihara-shi, Kanagawa 228-8555,2 Laboratory of Analytical Chemistry, School of Parmaceutical Sciences, Kitasato University, 108-8641 Shirogane, Minatoku, Tokyo, Japan4

Received 27 January 2003/ Returned for modification 29 August 2003/ Accepted 20 December 2003

Immature renal function in neonates requires antibiotic dosage adjustment. Population pharmacokinetic studies were performed to determine the optimal dosage regimens for three types of antibiotics: an aminoglycoside, arbekacin; a glycopeptide, vancomycin; and a carbapenem, panipenem. Eighty-three neonates received arbekacin (n = 41), vancomycin (n = 19), or panipenem (n = 23). The postconceptional ages (PCAs) were 24.1 to 48.4 weeks, and the body weights (BWs) ranged from 458 to 5,200 g. A one-compartment open model with first-order elimination was applied and evaluated with a nonlinear mixed-effect model for population pharmacokinetic analysis. In the fitting process, the fixed effects significantly related to clearance (CL) were PCA, postnatal age, gestational age, BW, and serum creatinine level; and the fixed effect significantly related to the volume of distribution (V) was BW. The final formulas for the population pharmacokinetic parameters are as follows: CLarbekacin = 0.0238 x BW/serum creatinine level for PCAs of <33 weeks and CLarbekacin = 0.0367 x BW/serum creatinine level for PCAs of >=33 weeks, Varbekacin = 0.54 liters/kg, CLvancomycin = 0.0250 x BW/serum creatinine level for PCAs of <34 weeks and CLvancomycin = 0.0323 x BW/serum creatinine level for PCAs of >=34 weeks, Vvancomycin = 0.66 liters/kg, CLpanipenem = 0.0832 for PCAs of <33 weeks and CLpanipenem = 0.179 x BW for PCAs of >=33 weeks, and Vpanipenem = 0.53 liters/kg. When the CL of each drug was evaluated by the nonlinear mixed-effect model, we found that the mean CL for subjects with PCAs of <33 to 34 weeks was significantly smaller than those with PCAs of >=33 to 34 weeks, and CL showed an exponential increase with PCA. Many antibiotics are excreted by glomerular filtration, and maturation of glomerular filtration is the most important factor for estimation of antibiotic clearance. Clinicians should consider PCA, serum creatinine level, BW, and chemical features when determining the initial antibiotic dosing regimen for neonates.

* Corresponding author. Mailing address: Department of Pharmacy, Kitasato University Hospital, 1-15-1 Kitasato, Sagamihara-shi, Kanagawa 228-8555, Japan. Phone: 81-42-778-8101. Fax: 81-427-78-9430. E-mail: gr4t-kmr{at}asahi-net.or.jp.

Antimicrobial Agents and Chemotherapy, April 2004, p. 1159-1167, Vol. 48, No. 4
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.4.1159-1167.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Tanigawara, Y., Sato, R., Morita, K., Kaku, M., Aikawa, N., Shimizu, K. (2006). Population Pharmacokinetics of Arbekacin in Patients Infected with Methicillin-Resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 50: 3754-3762 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»